Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26046044 | 0.83 | PDE4A (0.34) | PDE4ANPC1RAB9A | |
| SCHEMBL4520765 | 0.76 | GABRR1 (0.41) | PDE4APOLB | |
| SCHEMBL230823 | 0.74 | P2RX7 (0.33) | — | |
| SCHEMBL5114086 | 0.74 | PDE3B (0.37) | — | |
| SCHEMBL23374468 | 0.74 | HTT (0.34) | PDE4A | |
| SCHEMBL1808064 | 0.74 | PDE4A (0.33) | PDE4A | |
| SCHEMBL1808065 | 0.74 | NPC1 (0.34) | PDE4ANPC1RAB9A | |
| SCHEMBL5419514 | 0.73 | — | — | |
| SCHEMBL400853 | 0.73 | — | — | |
| SCHEMBL1333874 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434721-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-09-06 | — | — | US | disclosed |
| US-8604037-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8536177-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120015954-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120004217-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8008300-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7799786-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1810970-B1 | Therapeutic piperazine compounds | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-20100004254-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7582635-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. | 2009-09-01 | — | — | US | disclosed |
| US-20080153835-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-06-26 | — | — | US | disclosed |
| EP-1583763-B1 | BENZOAZOLYLPIPERAZINE DERIVATIVES HAVING VR1-ANTAGONIST ACTIVITY | EURO CELTIQUE SA (LU) | 2008-03-26 | — | — | EP | disclosed |
| EP-1556354-B1 | THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-01-23 | — | — | EP | disclosed |
| US-7279493-B2 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | EURO-CELTIQUE S.A. | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015954-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CDR2, GRIN1, HRH2 | PDE4A 2569/4885NPC1 1278/4885GAA 1603/4885 |
| US-20100004254-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CDR2, GRIN1, HRH2 | PDE4A 2569/4885NPC1 1278/4885GAA 1603/4885 |
| US-20080153835-A1 | Therapeutic agents useful for treating pain | CHRM2, CHRM1, MC1R | PDE4A 2257/4885NPC1 2203/4885GAA 1471/4885 |
| US-20120004217-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CDR2, GRIN1, HRH2 | PDE4A 2569/4885NPC1 1278/4885GAA 1603/4885 |
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRM2, CHRM1, MC1R | PDE4A 2257/4885NPC1 2203/4885GAA 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.